An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. A shift to a preventative approach is necessary for the efficiency and sustainability of our healthcare systems. Central to this shift is the often-underutilized tool of life-course immunization.
Long-term COVID-19 effects have been decreased from anywhere between 50 and 80% for those who have been vaccinated when compared to unvaccinated people.
Using almost $30 million in funding, an all-in-one vaccine is being developed to bring new protection against a range of new and existing coronavirus variants.
The most recent omicron subvariants have caused new infection spikes across the United States, as researchers find they are better at eluding vaccines.
A Phase 1 clinical trial of a universal flu vaccine has started inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Maryland.
Gaspary Mwanyika from the SACIDS Foundation for One Health, Sokoine University of Agriculture, Tanzania details the importance of genomic characterisation in the control of dengue.
